NASDAQ:OMED - Oncomed Pharmaceuticals Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.89
0.00 (0.00 %)
(As of 08/22/2019 03:16 PM ET)
Today's Range
$0.89
Now: $0.89
$0.89
50-Day Range
$0.89
MA: $0.89
$0.89
52-Week Range
$0.55
Now: $0.89
$3.35
VolumeN/A
Average Volume768,904 shs
Market Capitalization$34.43 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86
OncoMed Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OMED
CUSIPN/A
Phone650-995-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$44.42 million
Book Value$1.25 per share

Profitability

Net Income$-8,100,000.00

Miscellaneous

Employees22
Market Cap$34.43 million
Next Earnings DateN/A
OptionableOptionable

Receive OMED News and Ratings via Email

Sign-up to receive the latest news and ratings for OMED and its competitors with MarketBeat's FREE daily newsletter.


Oncomed Pharmaceuticals (NASDAQ:OMED) Frequently Asked Questions

What is Oncomed Pharmaceuticals' stock symbol?

Oncomed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED."

How were Oncomed Pharmaceuticals' earnings last quarter?

Oncomed Pharmaceuticals Inc (NASDAQ:OMED) posted its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported $0.16 EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.36. The biopharmaceutical company earned $19.52 million during the quarter, compared to analysts' expectations of $7.97 million. Oncomed Pharmaceuticals had a negative return on equity of 13.14% and a negative net margin of 18.24%. View Oncomed Pharmaceuticals' Earnings History.

What price target have analysts set for OMED?

2 brokerages have issued twelve-month price objectives for Oncomed Pharmaceuticals' shares. Their predictions range from $1.50 to $2.00. On average, they anticipate Oncomed Pharmaceuticals' share price to reach $1.75 in the next twelve months. This suggests a possible upside of 96.6% from the stock's current price. View Analyst Price Targets for Oncomed Pharmaceuticals.

What is the consensus analysts' recommendation for Oncomed Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncomed Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Oncomed Pharmaceuticals.

Has Oncomed Pharmaceuticals been receiving favorable news coverage?

Press coverage about OMED stock has been trending positive recently, InfoTrie reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oncomed Pharmaceuticals earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the near future. View News Stories for Oncomed Pharmaceuticals.

Who are some of Oncomed Pharmaceuticals' key competitors?

What other stocks do shareholders of Oncomed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncomed Pharmaceuticals investors own include Esperion Therapeutics (ESPR), NXP Semiconductors (NXPI), GW Pharmaceuticals PLC- (GWPH), Celldex Therapeutics (CLDX), Nightstar Therapeutics (NITE), Verastem (VSTM), Celgene (CELG), Clovis Oncology (CLVS), ImmunoGen (IMGN) and NewLink Genetics (NLNK).

Who are Oncomed Pharmaceuticals' key executives?

Oncomed Pharmaceuticals' management team includes the folowing people:
  • Mr. Perry A. Karsen, Exec. Chairman (Age 64)
  • Ms. Jill Henrich, Sr. VP of Regulatory Affairs & Quality Assurance
  • Dr. Ann Kapoun Ph.D., Sr. VP of Translational Medicine

What is Oncomed Pharmaceuticals' stock price today?

One share of OMED stock can currently be purchased for approximately $0.89.

How big of a company is Oncomed Pharmaceuticals?

Oncomed Pharmaceuticals has a market capitalization of $34.43 million and generates $44.42 million in revenue each year. The biopharmaceutical company earns $-8,100,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Oncomed Pharmaceuticals employs 22 workers across the globe.View Additional Information About Oncomed Pharmaceuticals.

What is Oncomed Pharmaceuticals' official website?

The official website for Oncomed Pharmaceuticals is http://www.oncomed.com/.

How can I contact Oncomed Pharmaceuticals?

Oncomed Pharmaceuticals' mailing address is 800 Chesapeake Drive, Redwood City CA, 94063. The biopharmaceutical company can be reached via phone at 650-995-8200 or via email at [email protected]


MarketBeat Community Rating for Oncomed Pharmaceuticals (NASDAQ OMED)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  287 (Thanks for Voting!)
Underperform Votes:  241 (Thanks for Voting!)
Total Votes:  528
MarketBeat's community ratings are surveys of what our community members think about Oncomed Pharmaceuticals and other stocks. Vote "Outperform" if you believe OMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel